

(51) International Patent Classification:  
C12N 5/071 (2010.01)(21) International Application Number:  
PCT/US2010/054450(22) International Filing Date:  
28 October 2010 (28.10.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
61/256,846 30 October 2009 (30.10.2009) US(71) Applicant (for all designated States except US): **THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL** [US/US]; Campus Box 4105, 308 Bynum Hall, Chapel Hill, NC 27599 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **REID, Lola, M.** [US/US]; 3621 Sweeten Creek Road, Chapel Hill, NC 27514 (US). **WANG, Yunfang** [CN/CN]; Rm 506, Building 7, 27 Taiping Road, Haidian Qu, Beijing, 27517 (CN). **CARDINALE, Vincenzo** [IT/IT]; Street Carlo Alberto Dalla Chiesa 9, Vallata, Avellino 83059 (IT). **GAUDIO, Eugenio** [IT/IT]; Via G. Tuccimei, 1, Rome 00197 (IT). **CARPINO, Guido** [IT/IT]; Via Moricone, 16,Rome 00199 (IT). **ALVARO, Domenico** [IT/IT]; Street Roberto Rossellini 51, Rome 00137 (IT). **CUI, Cai-Bin** [CN/US]; The University of North Carolina at Chapel Hill, Campus Box 4105, 308 Bynum Hall, Chapel Hill, NC 27599 (US).(74) Agents: **VILLACORTA, Gilberto, M.** et al.; Foley & Lardner LLP, 3000 K Street NW, Washington, DC 20007 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,

[Continued on next page]

(54) Title: MULTIPOTENT STEM CELLS FROM THE EXTRAHEPATIC BILIARY TREE AND METHODS OF ISOLATING SAME




FIG. 1

(57) **Abstract:** The present invention relates to a multipotent stem cell, multipotent cell populations, and an enriched multipotent cell population, each found in fetal, neonatal, pediatric, and adult biliary tree tissue and up to 72 hours post mortem (although preferentially, within 10 hours post mortem) and capable of maturing into multiple endodermal tissues that include liver, biliary and pancreatic tissues. The multipotent stem/progenitor cell and cell populations are found in peribiliary glands, and progenitors descending from them are present throughout the biliary tree including in the gallbladder. High numbers of the peribiliary glands are found in the branching locations of the biliary tree such as hilum, common hepatic duct, cystic duct, common duct, common hepato-pancreatic duct and gallbladder. Related multipotent cells, multipotent cell populations and their descendent progenitors are found throughout the biliary tree including in the gall bladder, which does not have peribiliary glands. Compositions comprising same, methods of identifying and isolating same, maintaining same in culture, expanding same in culture and differentiating or lineage restricting the same in vitro or in vivo to hepatic, biliary or pancreatic fates (e.g., as hepatocytes, cholangiocytes, and/or pancreatic islet cells) are also provided. Methods of using the multipotent cells and/or multipotent cell populations are also provided.



SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, —  
GW, ML, MR, NE, SN, TD, TG).

*before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments (Rule 48.2(h))*

**Published:**

— *with international search report (Art. 21(3))*

## MULTIPOTENT STEM CELLS FROM THE EXTRAHEPATIC BILIARY TREE AND METHODS OF ISOLATING SAME

### CROSS-REFERENCE TO RELATED PATENT APPLICATIONS

[0001] This application claims priority from US Provisional Application 61/256,846, filed October 30, 2009, incorporated herein by reference in its entirety.

### FIELD OF THE INVENTION

[0002] The present invention relates generally to multipotent progenitor cells, including multipotent stem cells, and cell populations comprising such progenitors or stem cells, in the biliary tree, liver and pancreas. More particularly, the present invention relates to multipotent progenitors or stem cells and cell populations comprising such progenitors or stem cells derived from portions of the extrahepatic biliary tree. It includes compositions comprising same and methods of identifying, isolating, maintaining, expanding and differentiating such cells and cell populations *in vitro* and *in vivo*.

### BACKGROUND OF THE INVENTION

[0003] Dead, dying, or dysfunctional cells are the cause of many known diseases, including diabetes and Alzheimer's diseases. One method of treating these ailments has focused on transplanting whole organs or parts thereof from donors to replace some or all of the functions of the "diseased" cells. Though often successful in stemming or retarding the course of some diseases, organ transplantation is accompanied by sizable morbidity/mortality, as are all major surgical interventions, and survival of the transplant is dependent on chronic administration of potent, systemic immuno-suppressants that often result in undesirable side effects. No matter the success of these approaches, however, they are inherently limited by the availability of donors.

[0004] An alternate approach in "regenerative medicine" is the use of stem cells and progenitors to repopulate whole organs, parts thereof, or at least their functions. Indeed, stem cells can be injected or implanted with relatively minor surgical procedures, often with negligible occurrence of adverse events. Because stem cells are not immunogenic (or are minimally immunogenic), they require relatively little, if any, immunosuppressants for the initial seeding of the cells.

[0005] Stem cells are rare cells requiring precise technologies to isolate and well-defined conditions to propagate *in vivo* and *in vitro*. Therefore, there is an urgent need to establish

alternative and complementary sources of transplantable, functional stem cells and progenitor cells and tissue for clinical use.

### **SUMMARY OF THE INVENTION**

[0006] According to one embodiment of the present invention, a composition comprising mammalian multipotent stem/progenitor cells capable of differentiating into multiple endodermal lineages (*e.g.*, hepatic lineage, a biliary lineage, a pancreatic lineage, or a combination thereof) is provided, wherein the cells are obtained from biliary tree tissue (*e.g.*, any portion of the biliary tree, including the hilum, common hepatic duct, cystic duct, common duct, common hepato-pancreatic duct gall bladder and peribiliary glands or progenitor cells or stem cells derived from the peribiliary glands) of a mammal, including a human mammal, fetus, neonate, child (pediatric), adult, or a deceased person up to 72 hours post mortem. Compositions comprising a population of cells comprising such mammalian multipotent stem/progenitor cells and/or a population of mammalian cells enriched for such multipotent stem/progenitor cells are also provided.

[0007] The multipotent stem/progenitor cells may express: (i) at least one marker indicative of early stage liver cell lineages (*e.g.*, HNF6, HES1, CK19, albumin, or AFP); (ii) at least one marker indicative of early stage pancreatic cell lineages (*e.g.*, PDX1, PROX1, NGN3, or insulin); and at least one marker selected from those in categories (a) – (c): (a) at least one surface marker found on stem/progenitor cells (*e.g.*, CD133 (prominin), CD44H (hyaluronan receptor), N-CAM, CXCR4, or EpCAM); (b) at least one transcription factor indicative of endodermal stem/progenitors (*e.g.*, SOX 9, SOX17, or FOXA2), and (c) weak to moderate expression a pluripotency gene (*e.g.*, SOX2, NANOG, KLF4, OCT4A or OCT4). In some instances, the multipotent stem/progenitor cells can express one marker from each of categories (i), (ii) and (a) – (c). The expression may be determined by endpoint and quantitative RT-PCR assay and/or by immunohistochemistry of tissue *in vivo*, of freshly isolated cells, or of cultured cells

[0008] The multipotent cells may also express at least one of the following: (i) nuclear expression of telomerase protein; (ii) low to moderate levels of expression of pluripotency genes; (iii) nuclear or perinuclear expression of classic endodermal transcription factors (*e.g.*, SOX17, SOX 9, FOXA2, HES1, HNF6, PROX1, HNF3B (hepatocyte nuclear factor-3B, FOXA2, SALL4 (Sal-like protein 4), PDX 1, NGN3, or combinations thereof); (iv) expression of endodermal stem/progenitor surface markers; (v) lack of expression or expression of low and variable levels of lineage markers of mature liver (P450-3A4,



transferrin, tyrosine aminotransferase (TAT) and high levels of albumin; lineage markers for mature bile duct comprise AE2, CFTR, secretin receptor, aquaporins, or combinations thereof), mature bile duct, or mature endocrine pancreas (*e.g.*, insulin, glucagon, somatostatin, amylase or combinations thereof); (vi) lack of expression of markers for mesenchymal cells, endothelial cells or hemopoietic cells.

**[0009]** In another embodiment of the invention, a method of obtaining, isolating, and/or identifying a mammalian multipotent stem/progenitor cells capable of differentiating into multiple endodermal lineages is provided, wherein the cells are obtained from biliary tree tissue (*e.g.*, the biliary tree tissue comprises hilum, common hepatic duct, cystic duct, common duct, common hepato-pancreatic duct and gallbladder, or combinations thereof) of a mammal, the method comprising obtaining biliary tree tissue, and sequentially, and in any order, or substantially simultaneously obtaining cells that are positive for: (i) at least one marker indicative of early liver cell lineage stages (*e.g.*, HNF6, HES1, CK19, albumin, or AFP); (ii) at least one marker indicative of early pancreatic cell lineage stages (*e.g.*, PDX1, PROX1, NGN3, or insulin); and optionally, at least one marker selected from (a) – (c): (a) at least one surface marker found on stem/progenitor cells (*e.g.*, CD133 (prominin), CD44H (hyaluronan receptor), N-CAM, CXCR4, or EpCAM); (b) at least one transcription factor indicative of endodermal stem/progenitors (*e.g.*, SOX 9, SOX17, or FOXA2), and (c) weak to moderate expression a pluripotency gene (*e.g.*, SOX2, NANOG, KLF4, OCT4A or OCT4). A method of identifying and isolating a population of mammalian multipotent cells enriched for the mammalian multipotent stem/progenitors is also provided.

**[0010]** According to the method, the basal medium may be any basal medium rich in nutrients and with no copper and low calcium (below 0.5 mM), preferably supplemented with insulin, transferrin/Fe, selenium, zinc, free fatty acids bound to serum albumin and, optionally, high density lipoprotein. An example of a basal medium is RPMI 1640. The cells may optionally be cultured on plastic alone or plastic coated with collagen IV, collagen III, laminin, hyaluronans, other matrix components from embryonic, fetal, neonatal tissues or combinations thereof. The cells are cultured for at least 24 hours and preferably 7-21 days. According to the method, the isolated cells are 80%, 90%, 95%, 95%, preferably 100% enriched for the stem cells of the present invention. The isolation may be carried out via immunoselection technology (*e.g.*, panning, magnetic bead selection, flow cytometry, or combinations thereof) and/or selective culture conditions.

**[0011]** In yet another embodiment of the present invention, a method of propagating and/or expanding the novel mammalian multipotent stem/progenitor cells, or a population

comprising such cells or enriched for such cells or a partner cell thereof (*e.g.*, mesenchymal cells, angioblasts and stellate cell precursors), comprising: culturing the cells on plastic or hyaluronans, or optionally on plastic coated with type III or IV collagen or hyaluronan or other matrix component derived from fetal, neonatal, or embryonic tissue and in a basal medium containing no copper, low calcium ( $<0.5$  mM), insulin, transferrin/Fe, a mixture of free fatty acids bound to serum albumin, and optionally, high density lipoprotein.

**[0012]** In still yet another embodiment of the invention, a method of lineage restricting the novel multipotent stem/progenitor cells to adult liver cell fates is provided. The method comprises (a) obtaining a cell suspension comprising mammalian multipotent stem/progenitor cells capable of differentiating into multiple endodermal lineages, wherein the cells are obtained from biliary tree tissue of a mammal; (b) embedding the cell suspension into a hydrogel comprising hyaluronan or hyaluronan combined with other matrix components (*e.g.*, type IV collagen, laminin, or both); and (c) culturing the cell suspension in basal medium supplemented with copper, calcium ( $\geq 0.5$  mM), insulin, transferrin/Fe, bFGF, hydrocortisone, glucagon, galactose, tri-iodothyroxine (T3), epidermal growth factor (EGF), hepatocyte growth factor (HGF), high density lipoprotein, and a mixture of free fatty acids bound to albumin, for a time sufficient to allow their differentiation into liver cells.

**[0013]** In still yet another embodiment of the invention, a method of lineage restricting the novel multipotent stem/progenitor cells to adult pancreatic cell fates is provided. The method comprises (a) obtaining a cell suspension comprising the mammalian multipotent stem/progenitor cells mammalian multipotent stem/progenitor cells capable of differentiating into multiple endodermal lineages, wherein the cells are obtained from biliary tree tissue of a mammal; (b) embedding the cell suspension into a hydrogel comprising hyaluronans or hyaluronans combined with other matrix components; and (c) culturing the cells in a basal medium supplemented with copper, calcium ( $\geq 0.5$  mM), B27, ascorbic acid, insulin, transferrin/Fe, bFGF, cyclopamine, retinoic acid, exendin 4, high density lipoprotein, and a mixture of free fatty acids bound to albumin; and lacking hydrocortisone for a time sufficient to allow their differentiation into pancreatic cells.

**[0014]** In still yet another embodiment of the invention, a method of lineage restricting the novel multipotent stem/progenitor cells to adult biliary cell fates is provided. The method comprises (a) obtaining a cell suspension comprising the mammalian multipotent stem/progenitor cells mammalian multipotent stem/progenitor cells capable of differentiating into multiple endodermal lineages, wherein the cells are obtained from biliary tree tissue of a mammal; (b) embedding the cell suspension into a hydrogel comprising hyaluronans or

hyaluronans in combination with other matrix components (e.g., type I collagen); and (c) culturing the cells in a basal medium supplemented with copper, calcium ( $\geq 0.5$  mM), insulin, transferrin/Fe, hydrocortisone, bFGF, vascular endothelial cell growth factor (VEGF), hepatocyte growth factor (HGF), high density lipoprotein, and a mixture of free fatty acids bound to albumin, for a time sufficient for their differentiation into cholangiocytes.

[0015] In still yet another embodiment of the invention, a method of differentiating cells *in vivo* is provided, comprising transplanting the mammalian multipotent stem/progenitor cells, or populations comprising such cells or enriched for such cells, *in vivo* as cell suspensions or as implants or grafts, with or without prior lineage restriction under appropriate culture conditions, into the liver where they differentiate to liver tissue.

[0016] In still yet another embodiment of the invention, a method of differentiating cells *in vivo* is provided, comprising transplanting the mammalian multipotent stem/progenitor cells of Claim 1, or populations comprising such cells or enriched for such cells, *in vivo* as cell suspensions or as implants or grafts, with or without prior lineage restriction under appropriate culture conditions, into the bile duct where they differentiate into biliary tree tissue.

[0017] In still yet another embodiment of the invention, a method of differentiating cells *in vivo* is provided, comprising transplanting the mammalian multipotent stem/progenitor cells of Claim 1, populations comprising such cells or enriched for such cells, *in vivo* as cell suspensions or as implants or grafts, with or without prior lineage restriction under appropriate culture conditions into the pancreas, under the kidney capsule or into the epididymal fat pads, where they differentiate into functional pancreatic tissue.

[0018] In this respect, before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details of construction and to the arrangements of the components set forth in the following description or illustrated in the drawings. The invention is capable of embodiments in addition to those described and of being practiced and carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein, as well as the abstract, are for the purpose of description and should not be regarded as limiting.

[0019] As such, those skilled in the art will appreciate that the conception upon which this disclosure is based may readily be utilized as a basis for the designing of other structures, methods and systems for carrying out the several purposes of the present invention. It is important, therefore, that the claims be regarded as including such equivalent constructions insofar as they do not depart from the spirit and scope of the present invention.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

[0020] **Figure 1** is a schematic diagram depicting a multipotent biliary stem cell of the present invention having the capacity to differentiate into several types of endodermal tissues. All of the cells express “endodermal” (E) transcription factors (e.g. SOX 9, SOX 17, FOXA2) and other markers of stem/progenitor populations ( surface antigens such as CD133, CD44H, EpCAM, CXCR4, NCAM). Lineage restriction results in various adult fates including liver, pancreas, and biliary tree.

[0021] **Figure 2** is a schematic diagram of the biliary tree showing its connections with liver, pancreas and duodenum. Sites at which high numbers of peribiliary glands, the stem cell niches of the biliary tree, may be found are indicated by a star.

[0022] **Figure 3** is a composite of images of histology and immunohistochemistry of different regions of the biliary tree and that were used to identify markers and also the numbers and sizes of peribiliary glands throughout the biliary tree. (a) Distribution and characterization of peribiliary glands (PBGs) in the extrahepatic biliary tree. PBGs are present in the duct walls of the biliary tree and are sites for biliary tree stem/progenitors. A survey was done (n= 5 human biliary trees examined) of the numbers and sizes of the peribiliary glands at varying sites within the biliary tree, of marker profiles of the PBGs. The density of PBGs, expressed as surface occupied by PBGs acini/total area as evaluated by imaging analysis; the number and circumference were histologically analyzed in the different sites of the human extrahepatic biliary tree. The hepato-pancreatic ampulla showed the highest density and number of PBGs; roughly equal numbers were found in the cystic duct and hilum; less were found in bile duct; and none in gallbladder. \*p< 0.01. Original magnification x10. **b:** Immunohistochemistry of PBGs *in situ*. The PBGs are positive for CK7, CK19, NCAM, CD133, insulin, EpCAM, SOX9, SOX 17 and PDX1 but negative (or very low levels) for albumin. Variation in these early lineage markers (e.g. albumin) are seen among various peribiliary glands (see **Figure 7** for evidence with respect to albumin). Original magnification x 40.

[0023] **Figure 4** shows that the stem cells are located primarily within the peribiliary glands (PBGs). Note that there is variability within a single peribiliary gland in the expression of the stem cell markers, which in this case is PDX1. The red arrows indicate the nuclei of cells expressing the transcription factor; the black arrows indicate ones not expressing it.

[0024] **Figure 5** shows SOX17 (A) and PDX1 (B) along with EpCAM (green) and nuclei stained blue with 4',6-diamidino-2-phenylindole (DAPI) in peribiliary glands of cystic duct.

[0025] **Figure 6** provides immunohistochemistry data on human biliary tissue and showing expression of EpCAM, SOX 9, and SOX17 in peribiliary glands in cystic duct and hilum.

[0026] **Figure 7** provides a summary of the key properties of the multipotent Biliary Tree Stem Cells. These include surface markers of stem/progenitors; transcription factors typical of endodermal progenitors; variable expression of early lineage stage markers of liver, biliary tree, and pancreas; and in **Figure 8** the weak to moderate expression of pluripotency genes. Representative RT-PCR assays for hepatic hilum indicate a broad repertoire of endodermal transcription factors (SOX 9, SOX 17, FOXA2, PDX1, NGN3, etc.) and classic stem/progenitor surface markers (e.g. EpCAM, NCAM, CXCR4, CD133).

[0027] **Figure 8** shows RT-PCR data indicating expression of pluripotency genes by cystic duct and hilum tissue. Their weak to moderate expression provides additional evidence for the ability of the Biliary Tree Stem Cells to self-replicate. Pluripotency genes are ones found expressed in embryonic stem (ES) cells and ones able to yield induced pluripotent stem (iPS) cells if varying combinations of these genes are transfected into somatic cells. At least 5 genes have been identified: OCT 4, SOX2, NANOG, KLF4 and c-MYC. Weak to moderate levels of expression occur in biliary tree tissue and in isolated Biliary Tree Stem Cells for OCT 4, SOX2, NANOG, KLF4, but not c-MYC.

[0028] **Figure 9.** Gallbladder does not contain peribiliary glands (as shown also in **Figure 3**). However, cells expressing some of the stem/progenitor transcription factors and surface markers are present in gallbladder cells. Note that the brownish stain indicative of expression of the marker assayed (EpCAM or PDX1) is present in the cells at the surface of the gallbladder.

[0029] **Figure 10** shows immunohistochemistry data on gallbladder tissue that has no peribiliary glands. **(a,c,d).** The cells are positive for EpCAM (green) and have perinuclear staining for endodermal transcription factors (shown is SOX 17-red). **(b)** the cells also express PDX1 (pink) and are markedly proliferative as indicated by Ki67 staining (green).

[0030] **Figure 11.** Stem/progenitor cell colonies from biliary tree tissue. Cells were isolated and cultured in serum-free Kubota's Medium and on culture plastic. Three distinct colony types, Types 1-3, were observed under these conditions that are not permissive for mature cells but rather select for endodermal stem/progenitors. Immunohistochemical staining indicates expression for specific genes indicated by text in the color indicated for the marker. All sections are stained with 4',6-diamidino-2-phenylindole (DAPI) providing a blue color indicating nuclei. Colony type 1 (a) aggregates of cells strongly expressing EpCAM, NCAM, and ASBT. The cells grew slowly (with divisions every 3-4 days or longer). Colony

type 2 cells (b) with a phenotype closely similar to that of hHpSCs and with 100% of the cells expressing EpCAM, NCAM but none expressing AFP (with divisions every 36-40 hours).

Colony type 3 (c) are comprised of undulating, swirling cells with EpCAM expression at the edges but not interiors of the colonies and with high levels of expression of SOX 17, PDX1, or SOX 9 in the interior cells (with divisions every 36-40 hours). The magnification for all of the images is 20X. Pictures are representative of findings from more than 10 experiments in which the colonies were monitored for 4-8 weeks.

**[0031]** Evidence of a relationship between cells of colony types 2 and 3 is shown in a low magnification (4X) image (d). It is unknown if one is a precursor of the other. RT-PCR assays (e) indicate the expression of diverse genes in the colonies from cystic duct versus from gall bladder. The RT-PCR assays from the two tissues are quite similar, but those from cystic duct have weak expression of albumin and insulin, two genes not expressed by progenitor cells which were obtained from the gallbladder and growing in serum-free Kubota's Medium and on plastic.

**[0032] Figure 12.** The Biliary Tree Stem Cells, especially those of type 2 and 3 colonies, expand steadily for months resulting in colonies of cells with stable expression of stem/progenitor markers. This is partial evidence for self-replication of the cells; additional evidence is provided by the expression of pluripotency genes (**Figure 8**). Here is shown a type 3 colony after a month in culture with maintenance of expression of PDX1 (orange/red) in the cells that are at the center of the colony and with EpCAM (green) expressed only at the edges of the colony, sites at which there is slight differentiation. DAPI staining (blue) indicates the nuclei of the cells.

**[0033] Figure 13.** Phase micrograph of a biliary tree stem cell colony in culture for more than 8 weeks on culture plastic and in serum-free Kubota's Medium. The colony was initiated from 1-2 cells derived from adult human biliary tree tissue. To estimate the number of cells within the colony, magnified images were prepared from multiple regions of the colony (representative ones are indicated in the rectangular areas demarcated by colored outlines) and these areas imaged with Metamorph software and used to obtain cell numbers. The sampling of regions resulted in estimates of more than 500,000 cells in the colony. From fetal biliary tree tissue, we observe routinely >50 such colonies; from cystic duct and hilum tissue from adults, we routinely obtain >100 such colonies.

**[0034] Figure 14.** Location of transcription factors (or of telomerase protein) in tissue (*in situ*) or in cultures of Biliary Tree Stem Cells. Immunohistochemistry revealed that the transcription factors and telomerase protein were present intranuclearly in some cells and

perinuclearly or cytoplasmically in others. The significance of this is not known, though we hypothesize that nuclear localization implicates an active factor and perinuclear or cytoplasmic location might be a storage form. In these images, SOX 17 is expressed within the nucleus of some, but not all, of the cells of a peribiliary gland *in vivo* (*in situ* data) and is expressed within the nucleus of all of the Biliary Tree Stem Cells in culture on plastic and in Kubota's Medium. In the images of the cultures, the nuclei are blue from staining with DAPI; some of the cells express EpCAM (green); but all have intranuclear localization of SOX 17 (red). When the images are merged, the nuclei appear pink in color (merged blue and red colors).

**[0035] Figure 15.** Type 3 colony of Biliary Tree Stem Cells demonstrating both nuclear and perinuclear localization of the transcription factor, SOX 17 (red/pink). The cells at the perimeter of the colony are positive for EpCAM (green). The nuclei are stained blue with DAPI

**[0036] Figure 16.** *In situ* staining of gallbladder cells demonstrating only perinuclear and cytoplasmic staining of SOX 17 (red/orange). The cell membranes are positive for EpCAM (green), and the nuclei are stained blue with DAPI.

**[0037] Figure 17.** Multipotentiality of the Biliary Tree Stem Cells. Effects of Hormonally Defined Media (HDM) alone on differentiation to an hepatocytic or cholangiocytic fate. The stem cells remain indefinitely as stem/progenitors if cultured on plastic and in Kubota's Medium. They will differentiate towards an adult fate if the medium is changed to a hormonally defined medium (HDM) tailored for an adult fate. They will differentiate faster and more efficiently to an adult fate if the HDM is used in combination with plating the cells on or embedding them into forms of extracellular matrix (**Figures 20-22**). In these studies are shown representative data indicating the effect of a specific HDM on the differentiation of the biliary tree stem/progenitors towards an hepatocytic (HDM-L) versus cholangiocytic (HDM-C) fate.

**[0038]** Biliary tree stem/progenitors from colonies maintained under self-replication conditions (culture plastic and serum-free Kubota's Medium or its equivalent) were transferred either in HDM tailored for either hepatocytes (HDM-L), the upper row of images, or for cholangiocytes (HDM-C), the lower panel of images. **HDM-L Effects.:** Immunofluorescence (a) after 7 days. Cells were diffusely positive for CK18 (red) and/or albumin (blue-green). Magnification: 20X. Semi-quantitative data (c) comparing the numbers of hepatocytes (CK18+/albumin+ cells) under self-replication conditions (score: 0) versus in

HDM-L (score:  $2.2 \pm 0.8$ ), findings that translate to >20% of the cells having lineage restricted to an hepatocytic fate. **HDM-C effects:** Immunofluorescence (b) after 7 days. Cells were diffusely positive for CK7, secretin receptor (SR), and CFTR. They co-expressed CK7/SR and CK7/CFTR. Original Magnifications are 20X except for c4 and c5 that are 40X. Semi-quantitative estimate (c) of % of SR+/CFTR+ cells in the conditions for self-replication ( $0.2 \pm 0.4$ ; <5% of the cells) versus in the HDM-C ( $3 \pm 0.7$  which equates to over 30 % of the cells lineage restricting to cholangiocytes.

[0039] **Figure 18.** Multipotentiality of the Biliary Tree Stem Cells. Effects of Hormonally Defined Medium tailored to pancreas (HDM-P) alone on differentiation to a pancreatic fate.

**HDM-P Effects:** Immunofluorescence for pancreatic markers after 7 days of culture in HDM-P. At the periphery of the colonies, cell aggregation and condensation occurred to form Islet-like structures (a-d) containing c-peptide (a,b), PDX-1 (c) and insulin (d). Undifferentiated cells (EpCAM+ cells) were found within the colony centers (e). Original Magnifications: 20X. The number of islet-like structures (f) found in the conditions for self-replication ( $1 \pm 0.7$ ; <10% of the cells) were much lower than that in the HDM-P ( $3.8 \pm 1.3$ ; ~40% of the cells). The levels of C-peptide (g) in ng/ $\mu$ g of protein under glucose concentrations found in all RPMI 1640 formulations (11.1 mM) for a 2 hour incubation in the conditions for self-replication was  $4.5 \pm 2.25$  versus  $12.3 \pm 1.9$  ng/ $\mu$ g in the HDM-P. The data are expressed as Means  $\pm$  Standard Error, N=4; \*p < 0.05. (h) Glucose stimulated c-peptide secretion was observed in the HDM-P controls with the levels of the c-peptide in the medium, in  $\mu$ g/l, at  $1.10 \pm 0.32$   $\mu$ g/l in low levels of glucose (5.5 mM) to  $1.92 \pm 0.43$   $\mu$ g/l in high glucose (22 mM) n=7; \*p < 0.01.

[0040] **Figure 19.** Multipotentiality of the Biliary Tree Stem Cells. Quantitative (q)-RT-PCR analyses for effects of medium alone. The assays were done on biliary tree stem cell cultures maintained under self-replication conditions (culture plastic and Kubota's Medium) versus in a serum-free, hormonally defined medium (HDM –L or HDM-C or HDM-P) alone tailored for hepatocytes, cholangiocytes versus pancreatic cells. The mRNA relative expression levels were calculated by ranking the normalized  $\Delta$ Ct values against the geometric mean of the three most stable housekeeping genes. The data are indicated plus or minus ( $\pm$ ) standard deviation. The significance levels for each of these was \*p<0.05. n= the number of experiment done.

[0041] **Figure 20.** Multipotentiality of the Biliary Tree Stem Cells. Effects of both an HDM and extracellular matrix components on the differentiation of the Biliary Tree Stem Cells.



The biliary stem cells were cultured on plastic and in Kubota's Medium or its equivalent (self-replication conditions) for over a month resulting in colonies such as the one in (a). Such a representative colony was dispersed, and the cells were transferred to one of 3 differentiation conditions, presented in a 3-dimensional (3-D) format and comprised of an HDM + matrix components tailored for the desired adult fate: one for cholangiocytes (b), hepatocytes (c), or for pancreatic  $\beta$ -cells (d). They were maintained for up to 9 days in culture and then assayed for tissue-specific fates which indicated that these Biliary Tree Stem Cells can lineage restrict to multiple adult fates (here provided the examples of cholangiocytes, hepatocytes or pancreatic  $\beta$ -cells) depending on the culture conditions. Row 3=dithizone (DTZ) staining. (indication of pancreatic  $\alpha$  and  $\beta$  cells). D=days in culture; Glu=glucagon; C-P= C-peptide, indicative of insulin secretion

**[0042] Figure 21.** Transmission electron microscopy of Biliary Tree Stem Cells under self replication conditions (a-b) vs ones in the 3-D differentiation conditions to yield mature liver cells (c-d). Large and polygonal cells were present and cell nuclei display one or more nucleoli. (c) Adjacent cells form well-defined bile canaliculi (*arrows*). Bile canaliculi are closed by junctional complexes (*arrowheads*). Few microvilli are present in the lumen. (d). Thus, the cells were able to mature to adult hepatocytes and intrahepatic cholangiocytes. Bar=2 $\mu$ m

**[0043] Figure 22.** Proof of multipotentiality of the biliary tree stem/progenitors as given by by quantitative (q)-RT-PCR analyses on cultures under self-replication versus 3-D differentiation conditions. **a.** The biliary tree stem/progenitors were cultured in Kubota's Medium and on plastic for 2 months (self-replication conditions). The colonies were either maintained in those conditions and thereby yielding biliary stem/progenitor cells (BP) or transferred into the 3-D Differentiation conditions for hepatocytes (B-L), cholangiocytes (B-C) or pancreatic islets (B-P), and all were cultured for an additional 2 weeks. The cultures were then prepared for qRT-PCR analyses of genes relevant to each of the adult fates. The data were prepared as histograms in which the levels of expression of the genes in the self-replication conditions (BP) were given the value of 1.0, and the value of each gene in cells after differentiation to an adult fate was given as the fold change relative to that in BPs. The asterisk on some of the histograms indicates those of statistical significance ( $p < 0.01$  or  $p < 0.001$ ). N=2, each experiment with triplicate samples. **BP** = biliary stem/progenitors; **B-C** = cells lineage restricted to bile duct (cholangiocytes); **B-L** = cells lineage restricted to liver (hepatocytes); **B-P** = cells lineage restricted to pancreas (islets). The genes assayed were **GGT1** = gamma glutamyl transpeptidase-1; **AE2** = anion exchanger 2; **CFTR** = cystic

fibrosis transmembrane conductance regulator; **HNF4a** = hepatocyte nuclear factor 4A; **AFP** = alpha-fetoprotein; **ALB**= albumin; **TF**= transferrin; **TAT** = tyrosine aminotransferase; **CYP3A4** = cytochrome P450 3A4; **pdx1**= Pancreatic and duodenal homeobox 1; **ISL-1** = ISL LIM homeobox 1; **NGN3** = neurogenin 3; **INS** = insulin; **GCG** = glucagon.

**[0044] Figure 23.** Multipotentiality of the Biliary Tree Stem Cells as indicated by *in vivo* studies: Hepatic Fate. Biliary tree stem cells were maintained in culture under self-replication conditions (Kubota's Medium or its equivalent and culture plastic) and then were injected into the livers of immunocompromised, adult mice with quiescent livers (that is, no liver injury was induced). Liver sections prepared from the mice were then analyzed by immunohistochemistry for human specific markers indicative of hepatocytes. In this image, the section was stained for Dako's Anti human Hepar-1. The sections revealed that one can identify  $6.52 \pm 2.5\%$  of the total area occupied by human hepatocytes positive for human Hepar-1, a classic hepatocyte marker.

**[0045] Figure 24.** Multipotentiality of the biliary tree stem cells as indicated by transplantation *in vivo*: Biliary Tree Fate. Biliary tree stem cells were maintained in culture under self-replication conditions (Kubota's Medium or its equivalent and culture plastic) and then were injected into the livers of immunocompromised, adult mice with quiescent livers (that is, no liver injury was induced). Liver sections prepared from the mice were then analyzed by immunohistochemistry for human specific markers indicative of cholangiocytes. Dako's anti-human CK7, a marker of cholangiocytes, was found on an average of  $12.7 \pm 5.5\%$  of all cholangiocytes. In comparing the evidence for human cholangiocytes in small versus large bile ducts, it was found that  $\sim 14.92 \pm 5.9\%$  cells in the large bile ducts and  $\sim 5.02 \pm 1.95\%$  of the cells in small bile ducts were positive for human CK7.

**[0046] Figure 25.** Multipotentiality of the biliary tree stem cells as indicated by transplantation *in vivo*: Pancreatic Fate. Biliary tree stem cells were maintained in culture under self-replication conditions (Kubota's Medium or its equivalent and culture plastic) and then were injected into the epididymal fat pads (EFP) of male Balb/C Rag2<sup>-/-</sup>/Il2rg<sup>-/-</sup> mice. Each mouse was injected with 200-400 neoislets, cell aggregates of Biliary Tree Stem Cells lineage restricted for 7-14 days towards a pancreatic islet fate in the 3-D differentiation conditions of an HDM-P plus a hydrogel containing hyaluronan, type IV collagen and laminin. Each neoislet was comprised of more than 1000 cells. The control mice were transplanted with Matrigel without cells. The mice were monitored daily for glucose levels and were hyperglycemic (600- 750 mg/dl) for about 3 months. By 3 months, the glucose levels in the transplanted mice had dropped to levels that were less than half that in the

controls. Glucose tolerance tests were performed at postoperative day 68 and 91 and showed significant blood levels of human C-peptide in experimental mice, and these levels were regulatable by glucose.

### **DETAILED DESCRIPTION OF THE INVENTION**

[0047] The present invention stems from the heretofore unexpected discovery of a multipotent stem or progenitor cell, and cell populations comprising such multipotent stem or progenitor cells, found within the biliary tree and having the capacity to differentiate into multiple endodermal lineages, including liver, pancreas, and biliary tree (**Figure 1**). In the interest of clarity for this application, the term “Biliary Tree Stem Cell” will be used herein to refer to the inventive mammalian multipotent stem or progenitor cell, cell populations comprising such inventive cells, and cells populations enriched for the inventive cells.

[0048] The novel, multipotent Biliary Tree Stem Cells can be isolated from any portion of the biliary tree tissue but are found at especially high numbers in the peribiliary glands and at the branching points of the tree, which are indicated by stars on the schematic image of **Figure 2**. The stars found on the smallest branching terminals within the liver refer to the canals of Hering, the stem cell niche for intrahepatic hepatic stem cells. The Biliary Tree Stem Cells are precursors to the intrahepatic hepatic stem cells.

#### **Cell Sourcing-Biliary tree**

[0049] The biliary tree or extrahepatic biliary tree system is comprised of a series of ducts connecting the duodenum to the liver and to the pancreas and including the gallbladder (see schematic in **Figure 2**). Throughout the biliary tree, within the duct walls, are peribiliary glands (**Figures 3-11**), which may be found in particularly high numbers at the branching sites such as the hilum, common hepatic duct, cystic duct, common duct, common hepato-pancreatic duct and gallbladder. Fluids from liver or from ventral pancreas are emptied into the duodenum via the Papilla of Vater. This entire group of structures, including the gallbladder, is referred to herein as the biliary tree.

[0050] All of the biliary tree (*e.g.*, the hilum, common hepatic duct, cystic duct, common duct, common hepato-pancreatic duct and gallbladder) have walls composed of dense, fibrous connective tissue and a lumen lined by a layer of highly columnar biliary epithelium supported by a conventional basement membrane. Smooth muscle cells are dispersed along the ducts particularly near the Papilla of Vater. Blood vessels, nerve fibers and some lymphoid cells are found occasionally in the duct walls. Peribiliary glands are found along the

entire length of the biliary tree and in especially high numbers in the common hepato-pancreatic duct and the hilum, common hepatic duct, cystic duct, common duct and gallbladder. **Figures 3-7.**

**[0051]** The gallbladder has different features (**Figures 9, 10**). The lumen is lined by columnar epithelia, a proper muscle layer and subserosal connective tissue. No peribiliary glands are present in the gallbladder (**Figures 3, 9**). However, the gallbladder does have cells with overlapping phenotypes to those of the biliary tree stem cell populations found within the peribiliary glands are transit amplifying cells and/or committed progenitors.

**[0052]** The cells of the present invention may be isolated from biliary tree tissue of any stage of development. Thus, the instant invention may be practiced with fetal, neonatal, pediatric or adult tissue, including tissue from recently deceased individuals (preferably, within 10 hours, but the inventive cells remain viable for isolation of up to 72 hours post mortem). In fact, the biliary tree tissue is unique in that it is readily available from fetal, pediatric and adult donors. Furthermore, the present invention may be practiced with tissue from liver and pancreas organs obtained for, but then rejected for, transplantation, or from biopsy tissue, from resection tissue.

**[0053]** As well, the teachings herein are not limited or applicable to any one mammalian species. In fact, it should be understood that the examples provided herein are merely exemplary and should not be construed as limiting. The instant invention, in this way, is not limited by its mammalian source for biliary tree tissue. Mammals from which the Biliary Tree Stem Cells may be derived include, but are not limited to, humans, rodents (*e.g.*, rats, mice, hamsters), rabbits, cows, horses, pigs, sheep, dogs and cats. Preferably, the Biliary Tree Stem Cells are derived from humans for use in humans.

**[0054]** As noted, the novel class of Biliary Tree Stem Cells of the invention can be differentiated into multiple endodermal fates. Indeed, the Biliary Tree Stem Cells of the present invention may be induced to differentiate into mature cell types of several endodermal lineages including liver, biliary tree and pancreas. **Figures 17-25.**

**[0055]** Samples of biliary tree tissue can be dissected surgically from livers or pancreas obtained for and then rejected for transplant due to reasons such as steatosis; anatomical abnormality, or major vascular disease; or they can be obtained from resection material. They can be from gallbladders removed for various reasons. The biliary tree tissue can be removed from the connective tissue of the abdomen. The tissue is then divided into segments and processed further. Segments that are especially rich in the Biliary Tree Stem Cells include: the hilum, common hepatic duct, cystic duct, common duct, common hepato-

pancreatic duct and gallbladder. Each part can be further dissected into pieces cutting along the longitudinal diameter.

**[0056]** The Biliary Tree Stem Cells have been shown to give rise to multiple endodermal fates including liver, biliary tree and pancreas cells (**Figures 17-25**). The Biliary Tree Stem Cells express telomerase protein; low to moderate levels of pluripotency genes (Nanog, SOX2, KLF4 and OCT4—**Figure 8**); classic endodermal transcription factors (*e.g.*, SOX17, SOX 9, FOXA2, HNF6, PROX1, HNF3B (hepatocyte nuclear factor-3B (a.k.a. FOXA2), SALL4 (Sal-like protein 4), PDX 1 and NGN3); endodermal surface markers (*e.g.*, CD326/Epithelial cell adhesion molecule or EpCAM; CD56/Neuronal cell adhesion molecule or NCAM); CXCR4; and several stem/progenitor genes (*e.g.*, CD44H-- hyaluronan receptors, and CD133, also called prominin). **Figures 7, 8, 9, 13.**

**[0057]** Furthermore, ostensibly due to their multipotency, the Biliary Tree Stem Cells express low and variable levels of early lineage markers of the liver (*e.g.*, HNF6, HES1, FOXA2, and variably albumin), bile duct (*e.g.*, cytokeratin 19), and endocrine pancreas (*e.g.*, PDX1, NGN3, SALL4, insulin). **Figures 7, 22**

**[0058]** Notably, the Biliary Tree Stem Cells express the transcription factors PDX1 and NGN3 (**Figure 3, 4, 7, 11**), known to be essential for development of the pancreas and the endocrine pancreas, respectively. However, the Biliary Tree Stem Cells do not express or only weakly express mature markers of cholangiocytes (*e.g.*, secretin receptor, aquaporins), hepatocytes (*e.g.*, albumin, tyrosine aminotransferase or TAT, transferrin, “late” P450s such as P450-3A4) or islet cells (*e.g.*, glucagon, somatostatin, amylase or high levels of insulin) (**Figures 3, 7, 13**). They do not express at all markers for mesenchymal cells (*e.g.*, CD146, desmin), endothelial cells (*e.g.*, VEGF receptor, CD31, Van Willebrand Factor) or hemopoietic cells (*e.g.*, CD45). The pattern of expression of the antigens is stable throughout the life of the cultures as long as they are maintained under self-replication conditions consisting of Kubota’s Medium or its equivalent and with a substratum of culture plastic or hyaluronans.

**[0059]** These expression patterns can be determined using endpoint and quantitative (q)-RT-PCR assays and by immunohistochemistry of tissue *in vivo*, of freshly isolated cells, or of cultured cells. The co-expression in cells within the same peribiliary gland of multiple markers of endodermal stem/progenitors (*e.g.*, SOX 9, SOX17, PDX1, NGN3, FOXA2) is a unique and surprising feature that is distinctive from the findings with respect to embryonic stem (ES) cells undergoing lineage restriction to pancreas and in which these transcription factors are observed sequentially, but not all at the same time. Furthermore, the expression of

these transcription factors is absent in mature biliary cells at the luminal surface of the bile ducts.

**[0060]** The Biliary Tree Stem Cells of the present invention, as explained above, are progenitors to mature endodermal tissues and share markers with cells of the multiple tissues to which they can give rise including liver, biliary tree, and pancreas.

**[0061]** In addition to their relative expression levels, the cellular localization of telomerase and of the transcription factors (*e.g.*, SOX 17, PDX1) expressed within the Biliary Tree Stem Cells changes from a nuclear localization to a perinuclear/cytoplasmic localization during maturation (See **Figure 7** and also **Figures 14-16**). Within a single peribiliary gland, one observes some cells with nuclear and some cells with perinuclear localization or with no expression of the given marker (**Figures 4, 6, 7, 14**). Without being held to or bound by theory, intranuclear localization is associated with more primitive cells than those with perinuclear localization of the transcription factor(s). The latter cells are assumed to be transitioning into a later lineage stage. Alternatively, the perinuclear localization could indicate that the factor(s) is in an inactive storage form that can be translocated to the nucleus under appropriate regenerative demands.

**[0062]** The instant invention provides techniques for the isolation and propagation of Biliary Tree Stem Cells. The stem cell populations from human biliary tree tissue were identified by culture selection technologies but can be isolated also by immunoselection technologies (*e.g.*, flow cytometry, panning, magnetic bead isolation). Alternatively, or in addition to immunoselection, the Biliary Tree Stem Cells of the present invention may be isolated by virtue of tissue culturing conditions. For example, cell suspensions prepared from the biliary tree tissue may be plated onto plastic or hyaluronans. In other embodiments, the plastic is coated optionally with collagen IV, collagen III, laminin, hyaluronans, other matrix components found in embryonic/fetal tissues, or combinations thereof.

**[0063]** The medium used for culture selection, serum-free Kubota's Medium or its equivalent, is strongly selective for the survival and proliferation of the Biliary Tree Stem Cells and their partner mesenchymal cells, angioblasts and stellate cell precursors, but is not selective for mature cells of the biliary tree. The essence of this medium is that it is any basal medium containing no copper, low calcium (<0.5mM), insulin, transferrin/Fe, free fatty acids bound to purified albumin and, optionally, also high density lipoprotein.

**[0064]** Kubota's Medium or its equivalent is serum-free and contains only purified and defined mix of hormones, growth factors, and nutrients. More specifically, the medium is comprised of a serum-free basal medium (*e.g.*, RPMI 1640) containing no copper, low

calcium (< 0.5 mM) and supplemented with insulin (5 µg/ml), transferrin/Fe (5µg/ml), high density lipoprotein (10 µg/ml), selenium ( $10^{-10}$  M), zinc ( $10^{-12}$  M), nicotinamide (5 µg/ml), and a mixture of free fatty acids bound to a form of purified albumin. The detailed methods for the preparation of this media have been published elsewhere, *e.g.*, Kubota H, Reid LM, Proceedings of the National Academy of Sciences (USA) 2000; 97:12132-12137, the disclosure of which is incorporated herein in its entirety by reference.

[0065] These conditions yield colonies of Biliary Tree Stem Cells that grow rapidly for weeks (more than 8 weeks), with proliferation rates estimated at a division every 36-40 hours.

**Figures 11-13.** The cultures are able to remain stably as stem/progenitors for more than 8 weeks (**Figure 13**), evidence that they are undergoing self-replication. This evidence for self-replication is further supported by the finding of weak to moderate levels of expression of pluripotency genes. **Figure 8.** The number of colonies obtained is highest in cultures from the portions of the biliary trees having large numbers of peribiliary glands and intermediate in those from sites other than the branching points of the biliary tree or from gall bladder with no peribiliary glands.

#### **Lineage Restriction and Differentiation to Adult Fates**

[0066] Consistent with the multipotency of the Biliary Tree Stem Cells, if a colony is maintained for weeks (*e.g.*, over a month in culture) under self-replication conditions and then the medium changed to a serum-free, hormonally defined medium (HDM) tailored for a specific adult cell type, the cells will partially differentiate towards the designated adult cell type (**Figures 17-19**). In an HDM for liver (HDM-L), 20-30 % of the cells acquired expression of cytokeratin 8 and 18 and albumin, whereas in an HDM for cholangiocytes (HDM-C), over half of them matured to cells expressing secretin receptor and CFTR. **Figure 17.** The level of expression of human albumin in the cultures in HDM-L and the expression of secretin receptor in those in HDM-C were significantly higher than those in Kubota's Medium or its equivalent (self-replication conditions) in assays using quantitative RT-PCR (**Figure 19**).

[0067] Partial lineage restriction of the cells towards a pancreatic islet fate occurred if the Biliary Tree Stem Cells were cultured in an HDM for pancreas (HDM-P). **Figure 18.** The differentiation occurred primarily at the edges of the colonies, sites at which aggregates of cells formed and inside which human C-peptide, PDX1, and insulin were found. More than half of the colonies of cells acquired the ability to produce human C-peptide (**Figure 18h and 18g**), indicative of human insulin synthesis, and this C-peptide synthesis was regulatable by

glucose levels (**Figure 18h**). The level of human insulin produced was significantly higher in the cultures in HDM-P as compared with those remaining as stem cells under self-replications conditions. (**Figure 19**).

[0068] The extent of multipotentiality was demonstrated more dramatically if the cells were placed into distinct 3-D differentiation conditions comprised of the specific HDM (HDM-L, HDM-C, HDM-P) in combination with embedding the cells in hydrogels containing specific extracellular matrix components tailored for the adult cell type of interest (**Figure 20**). The cells rapidly differentiated (*e.g.*, 7-10 days) to specific adult cell types – yielding cords of liver cells in HDM-L in combination with hydrogels of hyaluronans containing type IV collagen and laminin; branching bile ducts, *i.e.* biliary tree, in HDM-C in combination with hydrogels of hyaluronans containing type I collagen; or pancreatic neoislets (endocrine pancreas) if in HDM-P and in hydrogels containing type IV collagen and laminin.

[0069] Further evidence for the differentiation under the 3-D culture conditions was found for Biliary Tree Stem Cells under self-replication conditions (**Figure 21, a and b**) versus conditions tailored for hepatocytes (**Figure 21, c and d**) and then characterized by transmission electron microscopy. Transmission electron microscopy of Biliary Tree Stem Cells under self replication conditions (a-b) vs hepatocytes (c-d). Under differentiation conditions, large and polygonal cells were present, and cell nuclei display one or more nucleoli. Adjacent cells form well-defined bile canaliculi (arrows). Bile canaliculi are closed by junctional complexes (*arrowheads*). Few microvilli are present in the lumen. The bar on the figures is equal to 2  $\mu$ m.

[0070] Proof that the differentiation conditions resulted in functional adult cells is provided in **Figure 22** containing quantitative RT-PCR data from cultures either under self-replication conditions yielding biliary stem/progenitors (BP) versus under the 3-D conditions for liver (B-L), biliary tree/cholangiocytes (B-C), or pancreas (B-P). The top row indicates the dramatic increase in expression of classic liver genes---HNF4, AFP, albumin, tyrosine aminotransferase (TAT), transferrin (TF), and P450-3A4---in the cultures under conditions for liver but not under those for the stem/progenitors or for biliary tree or pancreas. By contrast, those plated under conditions for pancreas (second row) showed very dramatic increases in gene expression for PDX-1, ISL-1, NGN3, insulin, glucagon (GCG) under the conditions for pancreas (B-P) but not those for stem/progenitors or liver or biliary tree. Those plated under conditions for biliary tree demonstrated increases for expression of GGT1, AE2, CFTR. The cultures of Biliary Tree Stem Cells transferred again under the self-



replication conditions maintained high levels of EpCAM and low levels of all the adult-specific genes.

[0071] This multipotentiality is demonstrated also when the cells are transplanted *in vivo* (**Figures 23-25**). Human Biliary Tree Stem Cells were transplanted into immunocompromised mice and then tissues evaluated later for presence of engrafted mature human cells. Even in mice with quiescent livers, that is not subjected to liver injuries, the cells were able to engraft and mature into significant numbers of hepatocytes (**Figure 23**) and cholangiocytes (**Figure 24**). Moreover, the mice transplanted with the cells driven to a pancreatic fate were subjected to drugs that made them diabetic, and the transplanted cells were able to rescue them from the diabetic condition, and these cells proved to be responsive to glucose levels in terms of production of human C-peptide (**Figure 25**).

[0072] Although multiple precursors have been identified and shown to differentiate into mature liver cells, the Biliary Tree Stem Cells identified in the present application, and present in fetal, neonate, pediatric and adult tissues are the first stem cells and cell populations identified to date that can be isolated from adult tissues and proven able to differentiate to mature pancreatic cell types. These cells are also the first identified that can be used immediately in clinical programs for diabetes because of their demonstrated ability to be able to differentiate into pancreatic islet cells, their lack of tumorigenic potential (as exists for ES cells or cells that are transfected with genes critical for differentiation to pancreas), and lack of immunogenicity.

[0073] The Biliary Tree Stem Cells are the natural precursors to pancreas and can differentiate easily and rapidly (within a few days in cultures) to pancreatic fates merely by using specific micro-environmental conditions. Moreover, the transition to the clinic is also facilitated by the fact that the micro-environmental conditions needed are available in GMP forms and now are part of extant clinical therapies. Hence, at least one clinical application is the use of the Biliary Tree Stem Cells described herein for the complete or partial repopulation, rescue, support, repair, replacement or introduction of pancreatic beta-like cells for treatment of diabetes (**Figure 25**), or for forms of liver failure, insufficiency, or degeneration (**Figures 23 and 24**).

[0074] It should be apparent to one of ordinary skill in the art in view of the disclosure herein that the Biliary Tree Stem Cells have numerous applications in clinical therapy and treatment. The acquisition of the Biliary Tree Stem Cells can be a relatively non-invasive procedure and relatively harmless to the patient. The ability to propagate these biliary stem cells *in vitro* facilitates the ability to obtain sufficient cells for clinical programs (*e.g.*,  $10^6$ - $10^9$  cells). The

quantity of stem cells needed for cell therapy programs is readily generated within a few weeks after the cells are procured, processed and cultured as indicated in **Figure 13**.

[0075] The Biliary Tree Stem Cells provided for therapy can be prepared from a given donor and then given back to the same person, constituting autologous therapy with no immunological problems in terms of cell rejection, as cells and recipient are preferably genetically identical. Alternatively, the Biliary Tree Stem Cells or cell populations provided for therapy can be prepared from a given donor and then given to another person, constituting allogeneic therapy as the Biliary Tree Stem Cells are non-immunogenic or minimally immunogenic. Finally, the Biliary Tree Stem Cells according to the invention should be relatively risk-free in animal experimentation and in cultures with regard to oncogenic potential. In all *in vivo* studies to date, there has been no evidence at all of tumorigenic potential.

[0076] In another embodiment of the invention, the Biliary Tree Stem Cells or cell populations are used for the *in vitro* production of target endodermal cells and target endodermal tissue (*e.g.*, pancreas, liver, bile duct). Accordingly, the invention provides and encompasses methods of producing the “target” cells and tissues from the Biliary Tree Stem Cells or cell populations, which methods comprise the isolation of Biliary Tree Stem Cells, their incubation under conditions that drive their differentiation into the target tissue or cells of that tissue, and introduction of the cells into a patient in need thereof. Therefore, differentiated tissue cells, which are obtained by differentiation of the Biliary Tree Stem Cells according to the invention, are also subject of the present invention.

[0077] As noted above and demonstrated in **Figures 14-16**, for partial differentiation of the Biliary Tree Stem Cells towards a specific adult fate, according to the invention, one can use a defined medium (also called a Hormonally Defined Medium or HDM) containing a specific mix of nutrients, hormones and growth factors, ideally being serum-free, and tailored to drive the cells to the adult fate of interest. Representative HDM for hepatocytes, cholangiocytes versus pancreatic islets are given below. The HDM alone elicits some lineage restriction towards the desired adult fate but does not elicit full differentiation. Full differentiation occurs after transplantation *in vivo* or, if the cells are *ex vivo*, further requires use of a specific HDM in combination with a mix of extracellular matrix components, the exact composition of the mix being unique to the adult cell type desired, and the cells must be established in a three-dimensional format as described herein. **Figures 17-19**.

[0078] Particularly preferable forms of application for *in vivo* differentiation of the Biliary Tree Stem Cells or cell populations according to the invention are injection, infusion or

implantation by grafting method of the Biliary Tree Stem Cells or cell populations into one area of the body, in order to allow for the Biliary Tree Stem Cells to differentiate there, by direct contact with cells of the target lineage or infusion of the Biliary Tree Stem Cells or cell populations to allow for the Biliary Tree Stem Cells or cell populations to reach the target tissue.. For injection or infusion, the Biliary Tree Stem Cells can be administered in a medium with which they are compatible, such as Kubota's Medium (or equivalent) or one of the HDM, or in a graft or implant under conditions comprised of matrix components with which they are compatible.

### **Therapeutic applications**

[0079] For the therapeutic use of the target cells obtainable from the Biliary Tree Stem Cells or cell populations, according to the invention, a number of concepts are available (*see* Science 287: 1442-1446, 2000), which are encompassed by the present invention. Examples of relevant indications in this connection are: inborn errors of metabolism, liver failure, cirrhosis of the liver, pancreatic insufficiency, and diabetes.

[0080] The inventive Biliary Tree Stem Cells or cell populations can be introduced directly into or onto the organ to be reconstituted, renewed or repaired. The introduction can be carried out as cell suspensions, as grafts comprised of the Biliary Tree Stem Cells or cell populations incorporated into a mix of extracellular matrix components along with the HDM or as other types of scaffolds (*e.g.*, microcarriers, polylactides) or as infusions. The scaffolds are preferably biodegradable, so that they "disappear" from the body, while the newly introduced cells or cell populations grow together with the existing cells. Cells that may be reconstituted, rescued, supported, repaired, replaced or introduced in this manner, preferably by autologous transplant, include islet cells or other pancreas cells, hepatocytes or other liver cells, and cholangiocytes or other biliary tree cells. Reconstitution, rescue, repair, support, replacement, or introduction may follow partial surgical resection of an organ for repair after trauma or for supportive use, for example, in the case of lacking or insufficient organ function.

[0081] The Biliary Tree Stem Cells or cell populations according to the invention and target cells obtained from them can further be bound to implantable materials, in order to increase biocompatibility. Therefore, also implantable materials, when coated with the Biliary Tree Stem Cells, are subjects of the invention. The implantable materials can also be artificial and/or biological carrier or support materials, which contain the Biliary Tree Stem Cells or cell populations and/or target cells derived therefrom. In this regard, the carrier materials or

support materials can be microcarriers, supports, containers or chambers for insertion or implantation into the human body.

[0082] In one such embodiment of the invention, a container with islet cells derived from the Biliary Tree Stem Cells or cell populations is used for the production of a pharmaceutical construct for use as an artificial islet cell port chamber to supply insulin *in vivo*. In another embodiment of the invention, an infusion or graft of the Biliary Tree Stem Cells or cell populations is used to reconstitute, rescue, repair, support, replace, or introduce islets or islet cells *in vivo*. Similar constructs can be made with hepatocytes or cholangiocytes derived from the Biliary Tree Stem Cells according to the invention.

[0083] The target cells or cell populations obtained from the Biliary Tree Stem Cells cells according to the invention can in addition be used as cell cultures in bioreactors (*e.g.*, external to the body), for example in order to carry out detoxification reactions or to produce substances generated normally *in vivo* by the target cells or tissues. This form of use is particularly relevant in the case of acute conditions, for example, in the case of acute liver failure as a bioartificial liver or for severe diabetes as a bioartificial endocrine pancreas.

[0084] Finally, the multipotent Biliary Tree Stem Cells or cell populations according to the invention may be broadly applied in transgenic modification and therapy. According to one embodiment of the invention, the Biliary Tree Stem Cells, or cells or tissue differentiated therefrom, are transfected with one or more genes. In this way, one or more genes, which are required to maintain the metabolism of certain organs, such as for example liver or pancreas, are restored and/or supported or reintroduced. For example, stem cells or hepatocytes can be transfected with the FAH (fumaroylacetoacetate hydrolase) gene. In a FAH-deficient mouse model, the intrasplenic injection of 1000 FAH-positive donor hepatocytes is sufficient to completely reconstitute the liver and fully compensate for the metabolic defect leading to cirrhosis of the liver. Overturf, K., M. Al-Dhalimy, C.-N. Ou, M. Finegold, and M. Grompe. American Journal of Pathology 151:1273-1280 (1997). Alternatively, the Biliary Tree Stem Cells or cell populations can be prepared from a given donor and delivered to another person, constituting allogeneic therapy, in order to restore, support, or introduce in the recipient one or more genes required to maintain the metabolism of certain organs, such as, for example, the liver or pancreas.

[0085] The following examples are illustrative of the invention, but the invention is by no means limited to these specific examples. A person of ordinary skill in the art will find in these examples but one means to implement the instant invention. Further, while the instant examples have been presented in the context of non-humans for experimental convenience,

the methods and reagents described herein can be readily translated to human application(s) by one of ordinary skill in the art from the teachings disclosed below.

## **EXAMPLES**

### **EXAMPLE I – Cell preparation**

[0086] Enzymatic dissociation may be carried out in the presence of protease(s), such as collagenase(s), and/or nuclease(s), such as DNase. Methods of enzymatic dissociation of liver cells are described and practiced in the art. By way of example, methods for the isolation and identification of the hepatic progenitors have been described in, for example, USP No. 6,069,005 and USP Application Nos. 09/487,318; 10/135,700; and 10/387,547, the disclosures of which are incorporated herein in their entirety by reference. Indeed, various procedures exist for preparation of cell suspensions. It is to be understood, therefore, that the scope of the present invention is not to be limited to a specific method of procuring whole tissue or preparing cell suspensions thereof.

### **EXAMPLE II – 3D culture conditions**

[0087] 3-dimensional (3-D) gels may be formed by mixing the matrix components, the hormones, cytokines, growth factors, nutrients and the basal medium into hyaluronans that are liquid when not cross-linked and become gelled when cross-linked. The details of the preparation of these are published elsewhere, *e.g.*, W. S. Turner, E. Schmelzer, R. McClelland et al., J Biomed Mater Res B Appl Biomater 82B (1), 156 (2006); and W. S. Turner, C. Seagle, J. A. Galanko et al., Stem Cells 26 (6), 1547 (2008), the disclosures of which are incorporated herein in their entirety. The cultures are typically maintained for 2-4 weeks or longer and then analyzed by histology, gene expression assays such as endpoint and quantitative RT-PCR, immunofluorescence and protein expression assays such as Western blots, and metabolomic footprinting.

[0088] The major components of the gel complexes are forms of chemically-modified hyaluronans. Carbylan-S (or, CMHA-S) is a carboxymethylated hyaluronan derivative that has been modified with multiple thiols for crosslinking. All materials are commercially available from, at least, Glycosan Biosciences (Salt Lake City, Utah).

[0089] Briefly, in one embodiment, the hyaluronan-matrices are prepared by dissolving hyaluronan as a dry reagent in Kubota's Medium to give a 2.0% solution (weight/volume). Laminin (Sigma, St. Louis, Mo) may then be added at a concentration of 1.5 mg/ml and type IV collagen (Becton Dickinson, Bedford, Ma) at a concentration of 6 mg/ml. Cross-linking

occurs within hours at room temperature and with exposure to oxygen in the air or within minutes if exposed to a cross-linking reagent, *e.g.*, PEGDA (polyethylene glycol diacrylate). So, the solution should be kept chilled at 4 °C and contact with oxygen and/or with PEGDA avoided, if cross-linking is not desired.

[0090] Upon completion of the experiments, the cells may be recovered by digesting the hydrogels first with a mix of hyaluronidase (1 mg/ml), DNase (0.5 mg/ml), and dithiothreitol (40 mgs/ml) prepared in Kubota's Medium (without transferrin), followed by Liberase (0.5 mg/ml) prepared in Kubota's Medium without insulin and transferrin. The cells that are obtained in this manner are suitable for characterization by flow cytometry, RT-PCR, or immunohistochemistry.

### **EXAMPLE III – Evidence of multipotency**

[0091] After 7-30 days or longer of culturing Biliary Tree Stem Cells or cell populations under self-replication conditions (Kubota's Medium, or equivalent, in combination with culture plastic or hyaluronans), monolayer cultures of the remaining cells (*i.e.*, Biliary Tree Stem Cells) are transferred to a differentiation medium, wherein the stem cells undergo rapid shape changes and changes in gene expression within 48 hours. All the differentiation media consists of modifications to the medium used for self-replication (*e.g.*, Kubota's Medium or equivalent) such that the hormonally defined medium will contain the components in the self-replication medium plus supplementation with calcium ( $\geq 0.5$  mM), copper, bFGF; this is referred to as “modified medium”. To achieve a specific adult cell type, the following are required:

[0092] Liver: lineage restriction to liver fates (*e.g.*, hepatocytes) may be achieved by embedding the Biliary Tree Stem Cells into hydrogels of hyaluronans into which is mixed type IV collagen and laminin and with the “modified medium” further supplemented with glucagon, galactose, triiodothyroxine, epidermal growth factor (EGF) and hepatocyte growth factor (HGF). In one embodiment, the amount of ingredients are as follows: MKM supplemented with 7  $\mu$ g/L glucagon, 2g/L galactose,  $10^{-9}$  M triiodothyroxine 3, 10 ng/ml EGF and 20 ng/ml HGF.

[0093] Pancreatic tissue: lineage restriction to pancreatic fates (*e.g.*, islets) may be achieved by embedding the Biliary Tree Stem Cells into a hydrogel of hyaluronans containing type IV collagen and laminin and with the “modified medium” further changed to remove hydrocortisone and to contain B27, ascorbic acid, cyclopamine, Retinoic acid and exendin 4. In one embodiment, the amount of ingredients are as follows: MKM modified to remove

hydrocortisone and contain 2% B27, 0.1 mM ascorbic acid, 0.25  $\mu$ M cyclopamine, 0.5 $\mu$ M Retinoic acid and 50ng/ml exendin 4.

[0094] Biliary Tree/Cholangiocytes: similarly, the Biliary Tree Stem Cells can be lineage restricted to biliary fates (*e.g.*, cholangiocytes) by embedding the stem cells into hyaluronans mixed with type I collagen and in the “modified medium” further supplemented with vascular endothelial cell growth factor (VEGF) 165 and HGF. In one embodiment, the amount of ingredients are as follows: MKM further supplemented with 20 ng/ml vascular endothelial cell growth factor (VEGF) 165 and 10 ng/ml HGF.

#### **EXAMPLE IV – Transplantation**

[0095] Transplantation of cells from solid organs via grafting protocols are preferable over injection or infusion for many applications, although either mode of delivery is feasible. It has been found that the hydrogel cultures described hereinabove provide good conditions for grafting. The cells can be suspended in the un-crosslinked hyaluronans, mixed with other matrix components in medium comprising basal medium plus hormones, growth factors and other soluble signals tailored for expansion and/or differentiation.

[0096] The cell populations used for the transplantation preferably comprise Biliary Tree Stem Cells or cell populations that are transplanted along with (or without) their native mesenchymal partners (*e.g.*, angioblasts, stellate cells), derived from the target tissue (or other source) for the transplantation, and at ratios paralleling those found *in vivo*. Without being held to or bound by theory, it is believed that this combination of the stem cells and the partner mesenchymal cells provides the appropriate microenvironment for full maturation of tissues that are vascularized and able to function physiologically.

[0097] In one embodiment, for pancreatic grafts, implants, or injections, the cellular components of the grafts may consist of the Biliary Tree Stem Cells or cell populations co-seeded into the graft with human fetal or neonatal tissue-derived angioblasts (VEGFR<sup>+</sup>, CD117<sup>+</sup> cells) and stellate cells (CD146<sup>+</sup> cells) at an estimated ratio of those cell populations found *in vivo* in the tissue. The stem cell populations may be obtained from expanding cells in culture as described herein. The angioblasts and stellate cells may be immunoselected with magnetically activated cell sorting (MACS) system or flow cytometric sorts from freshly prepared cell suspensions of human fetal or neonatal pancreas tissue.

[0098] All of the biliary tree stem cell populations can be immunoselected for cells positive for a cell surface marker common to stem/progenitors (*e.g.*, CD133, CD44H, EpCAM, NCAM). In one embodiment, the cells are incubated at 4 °C for 20 minutes at a

concentration of 50  $\mu$ l for  $50 \times 10^6$  total cells in 500  $\mu$ l phosphate buffered saline (PBS) containing 0.5% bovine serum albumin and 2 mM EDTA with FITC-conjugated primary antibodies. The cells so labeled are reacted with magnetic beads using anti-FITC antibodies and then selected by Midi- or MiniMACS columns and separation units. All incubation and selection steps should be performed on ice with addition of 10% ACCUTASE (Innovative Cell Technologies, San Diego, CA) to prevent aggregation of cells. Alternatively, the cells can be labeled with a fluoroprobe-labeled antibody and the cells immunoselected using flow cytometer.

#### **EXAMPLE V – Media**

[0099] All media were sterile-filtered (0.22- $\mu$ m filter) and kept in the dark at 4°C before use. Kubota's medium (KM) consists of any basal medium (*e.g.*, RPMI 1640) with no copper, low calcium (<0.5 mM),  $10^{-9}$  M selenium, 4.5 mM nicotinamide, 0.1 nM zinc sulfate,  $10^{-8}$  M hydrocortisone, 5  $\mu$ g/ml transferrin/Fe, 5  $\mu$ g/ml insulin, a mixture of free fatty acids that are added bound to serum albumin (0.1%) and, optionally, 10  $\mu$ g/ml high density lipoprotein.

#### **EXAMPLE VI – Differentiation conditions**

[00100] Three dimensional cultures were established with hydrogels containing hyaluronans, other matrix molecules, hormones, growth factors, cytokines, all prepared in a medium. All of the hydrogels were made using modified Kubota's Medium (or equivalent) that was supplemented with calcium to achieve 0.6 mM concentration,  $10^{-12}$  M copper, and 10  $\mu$ m of basic fibroblast growth factor (bFGF) (referred to as modified KM or MKM):

[00101] Liver cells: MKM-L with 7 $\mu$ g/L glucagon, 2g/L galactose,  $10^{-9}$  M tri-iodothyroxine 3, 10 ng/ml epidermal growth factor (EGF) and 20 ng/ml hepatocyte growth factor (HGF). The matrix scaffolds consisted of 60% type IV collagen and laminin and 40% hyaluronans.

[00102] Biliary Tree/Cholangiocytes: MKM-C supplemented with 20 ng/ml vascular endothelial cell growth factor (VEGF) 165 and 10 ng/ml HGF. The matrix scaffolds consisted of 60% type I collagen and 40% hyaluronans.

[00103] Pancreas, islets: MKM-P (without hydrocortisone) further supplemented with 2% B27, 0.1 mM ascorbic acid, 0.25  $\mu$ M cyclopamine, 0.5 $\mu$ M RA and 50ng/ml exendin-4. The matrix scaffolds consisted of 60% type IV collagen and laminin and 40% hyaluronans.



**EXAMPLE VII – Cell isolation and phenotyping**

**[00104]** Human biliary tissues were obtained from livers and pancreases obtained for and then rejected for transplantation into a patient. Cell suspensions of human biliary tissues were processed using RPMI 1640 supplemented with 0.1% bovine serum albumin, 1 nM selenium and antibiotics. Enzymatic processing buffer contained 300U/ml type IV collagenase and 0.3 mg/ml deoxyribonuclease at 32 °C with frequent agitation for 15-20 min. Enriched suspensions were pressed through a 75 gauge mesh and spun at 1200 RPM for 5 min before resuspension. Estimated cell viability by trypan blue exclusion was routinely higher than 95%.

**[00105]** Approximately  $3 \times 10^5$  cells were plated on a 10 cm tissue culture dish and in serum-free Kubota's Medium, which was replaced every 3 days. Colonies formed within 5-7 days and were observed for up to 3 months. Colonies were picked by hand at varying times using an inverted microscope.

**[00106]** Multipotent Biliary Tree Stem Cells were also isolated by immunoselection from freshly prepared cell suspensions based on positive expression of one or more cell surface markers common to stem/progenitors (CD133, CD44H, NCAM, EpCAM-- CD326) using magnetic bead immunoselection technologies with the Miltenyi Biotech MACS system (Bergisch Gladbach, Germany) following the manufacturer's instructions. Briefly, dissociated cells were incubated with EpCAM antibody bound to magnetic microbeads for 30 min at 4 °C, and were separated using magnetic column separation system from Miltenyi following the manufacturer's recommended procedures. Medium was replaced daily and collected medium was stored at -20 °C for further analysis.

**[00107]** For the fluorescent staining, cells were fixed with 4% paraformaldehyde (PFA) for 20 min at room temperature, rinsed with HBSS, blocked with 10% goat serum in HBSS for 2 h, and rinsed. Fixed cells were incubated with primary antibodies at 4 °C over night, washed, incubated for 1h with labeled isotype-specific secondary antibodies, washed, counterstained with 4',6-diamidino-2-phenylindole (DAPI) for visualization of cell nuclei.

**[00108]** For immunohistochemistry, tissues were fixed in 4% paraformaldehyde (PFA) overnight, stored in 70% ethanol, and subsequently embedded in paraffin and cut into 5  $\mu$ m sections. Sections were deparaffinized, and the antigens were retrieved. Endogenous peroxidases were blocked by incubation for 30 min in 0.3% H<sub>2</sub>O<sub>2</sub> solution. After blocking with 10% horse serum, primary antibody was applied at 4 °C over night; secondary antibody and ABC staining were performed using the RTU Vectastain kit (Vector Laboratories,

Burlingame, CA). Vector Nova RED was used as substrate. Sections were dehydrated, fixed and embedded in Eukitt Mounting Media (Electron Microscopy Sciences, Hatfield, PA), and were analyzed using an inverted microscope.

**[00109]** For quantitative reverse-transcription polymerase chain reaction (RT-PCR) analysis, biliary tree tissue or cells from culture were lysed and total RNA extracted using RNeasy Plus Mini Kit (Qiagen GmbH, Valencia CA) as per the manufacturer's instructions. Reverse transcription was carried out with the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA). HotStarTaq Master Mix Kit (Qiagen) was used for PCR.

**[00110]** Cells were analyzed and sorted by a FACStar Plus cell sorter (BD Biosciences) equipped with dual Coherent I-90 lasers. Fluorescence-conjugated antibodies were excited at 488 nm, and their fluorescence emission was detected by standard filters.

**[00111]** While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to cover any variations, uses, or alterations of the invention following such as variations in the precise concentrations of matrix components or growth factors or hormones to elicit precise responses from the cells. In general, the principles of the invention, and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains, may be applied to the essential features hereinbefore set forth and as follows in the scope of the appended claims.

**[00112]** **Abbreviations:** **AE2**, anion exchanger 2; **AFP**,  $\alpha$ -fetoprotein; **ALB**, albumin; **ASMA**, alpha-smooth muscle actin; **ASBT**, Apical sodium-dependent bile acid transporter; **bFGF**, basic fibroblast growth factor; **CD**, common determinant; **CD133**, prominin; **CD146**, Mel-CAM; **CD31**, PECAM; **CD44H**, hyaluronan receptor; **CD45**, common leucocyte antigen; **CFTR**, cystic fibrosis transmembrane conductance regulator; **CK**, cytokeratin; **CXCR4**, CXC-chemokine receptor 4; **CYP450**, Cytochrome P450; **EGF**, epidermal growth factor; **EpCAM**, epithelial cell adhesion molecule; **FOXA2**, forkhead box a2; **GGT**, gamma glutamyl transpeptidase; **HDM**, hormonally defined medium, one tailored for a specific cell type; **HDM-L**, hormonally defined medium for liver; **HDM-C**, hormonally defined medium for cholangiocytes (biliary tree); **HDM-P**, hormonally defined medium for pancreas; **HGF**, hepatocyte growth factor; **HNF**, hepatocyte nuclear factor; **KM**, Kubota's Medium, a serum-free medium designed for stem/progenitors; **NCAM**, neural cell adhesion molecule; **NGN3**, neurogenin 3; **PDX1**, Pancreatic and duodenal homeobox 1; **PROX1**, Prospero homeobox

protein 1; **SALL4**, Sal-like protein 4; **SOX**, Sry-related HMG box; **SR**, secretin receptor; **VEGF**, vascular endothelial growth factor.

**We claim:**

1. A composition comprising mammalian multipotent stem/progenitor cells capable of differentiating into multiple endodermal lineages, wherein the cells are obtained from biliary tree tissue of a mammal.
2. The composition of Claim 1, in which the multipotent stem/progenitor cell is a multipotent stem cell.
3. The composition of Claim 1, in which the endodermal lineage is a hepatic lineage, a biliary lineage, a pancreatic lineage, or a combination thereof.
4. The composition of Claim 1, in which the biliary tree tissue is any portion of the biliary tree, including the hilum, common hepatic duct, cystic duct, common duct, common hepato-pancreatic duct and gall bladder.
5. The composition of Claim 1, in which the mammal is a human.
6. The composition of Claim 5, in which the human mammal is a fetus, neonate, child (pediatric), adult, or a deceased person up to 72 hours post mortem.
7. The composition of Claim 6, in which the mammal is a deceased person within 10 hours post mortem.
8. The composition of Claim 1, in which the biliary tree tissue contains peribiliary glands or progenitor cells or stem cells derived from the peribiliary glands.
9. The composition of Claim 1, in which the biliary tree tissue comprises locations at which the biliary tree branches.
10. The composition of Claim 1, in which the multipotent cells express:
  - (i) at least one marker indicative of early stage liver cell lineages;
  - (ii) at least one marker indicative of early stage pancreatic cell lineages; and at least one marker selected from those in categories (a) – (c):
    - (a) at least one surface marker found on stem/progenitor cells;
    - (b) at least one transcription factor indicative of endodermal stem/progenitors, and
    - (c) weak to moderate expression a pluripotency gene.
11. The composition of Claim 10, in which the at least one marker indicative of early stage liver cell lineages is HNF6, HES1, CK19, albumin, or AFP.

12. The composition of Claim 10, in which the at least one marker indicative of early stage pancreatic cell lineages is PDX1, PROX1, NGN3, or insulin.

13. The composition of Claim 10, in which at least one surface marker found on stem/progenitor cells is CD133 (prominin), CD44H (hyaluronan receptor), N-CAM, CXCR4, or EpCAM.

14. The composition of Claim 10, in which at least one transcription factor indicative of endodermal stem/progenitors is SOX 9, SOX17, or FOXA2.

15. The composition of Claim 10, in which the pluripotency gene is SOX2, NANOG, KLF4, OCT4A or OCT4.

16. The composition of Claim 1, in which the multipotent cells express:

- (i) at least one marker indicative of early stage liver cell lineages;
- (ii) at least one marker indicative of early stage pancreatic cell lineages;
- (iii) at least one surface marker found on stem/progenitor cells;
- (iv) at least one transcription factor indicative of endodermal stem/progenitors; and
- (v) weak to moderate expression of a pluripotency gene.

17. The composition of Claim 1, in which the multipotent cells express at least one of the following:

- (i) nuclear expression of telomerase protein;
- (ii) low to moderate levels of expression of pluripotency genes;
- (iii) nuclear or perinuclear expression of classic endodermal transcription factors;
- (iv) expression of endodermal stem/progenitor surface markers;
- (v) lack of expression or expression of low and variable levels of lineage markers of mature liver, mature bile duct, or mature endocrine pancreas;
- (vi) lack of expression of markers for mesenchymal cells, endothelial cells or hemopoietic cells.

18. The composition of Claim 10, in which the endodermal stem/progenitor surface markers comprise CD326/Epithelial cell adhesion molecule (EpCAM), CD56/Neuronal cell adhesion molecule (NCAM), CD133 (prominin), CD44H (hyaluronan receptor), CXCR4, or combinations thereof.

19. The composition of Claim 10, in which the classic endodermal transcription factors comprise SOX17, SOX 9, FOXA2, HES1, HNF6, PROX1, HNF3B (hepatocyte

nuclear factor-3B, FOXA2, SALL4 (Sal-like protein 4), PDX 1, NGN3, or combinations thereof.

20. The composition of Claim 10, in which the lineage markers of mature liver comprise P450-3A4, transferrin, tyrosine aminotransferase (TAT) and high levels of albumin; lineage markers for mature bile duct comprise AE2, CFTR, secretin receptor, aquaporins, or combinations thereof; and the lineage markers for mature pancreas comprise high levels of insulin, glucagon, somatostatin, amylase or combinations thereof.

21. The composition of Claim 10, in which the markers for mesenchymal cells comprise CD146, desmin, alpha-smooth muscle actin (ASMA) , or combinations thereof; the markers for endothelial cells comprise VEGF receptor, CD31, Van Willebrand Factor, or combinations thereof; and a generic marker for hemopoietic cells is CD45.

22. The composition of Claim 10, in which the expression is determined by endpoint and quantitative RT-PCR assay and/or by immunohistochemistry of tissue *in vivo*, of freshly isolated cells, or of cultured cells.

23. The composition of Claim 10, in which the biliary tree tissue comprises cystic duct, hilum, common hepatic duct, common hepato-pancreatic duct, gall bladder, and any portions of the biliary tree connecting them or combinations thereof.

24. The composition of Claim 10, in which the biliary tree tissue comprises locations where biliary tree branches.

25. A composition comprising a population of cells comprising mammalian multipotent stem/progenitor cells according to Claim 1.

26. A composition comprising a population of mammalian cells enriched for multipotent stem/progenitor cells according to Claim 1.

27. A method of obtaining a mammalian multipotent stem/progenitor cells capable of differentiating into multiple endodermal lineages, wherein the cells are obtained from biliary tree tissue of a mammal, the method comprising obtaining biliary tree tissue, and sequentially, and in any order, or substantially simultaneously obtaining cells that are positive for:

- (i) at least one marker indicative of early liver cell lineage stages;
  - (ii) at least one marker indicative of early pancreatic cell lineage stages; and
- optionally,

at least one marker selected from (a) – (c):

- (a) at least one surface marker found on stem/progenitor cells;
- (b) at least one transcription factor indicative of endodermal stem/progenitors, and
- (c) weak to moderate expression a pluripotency gene.

28. The method of Claim 27, in which the isolation is via immunoselection technology and/or selective culture conditions.

29. The method of Claim 28, in which the immunoselection technology comprises panning, magnetic bead selection, flow cytometry, or combinations thereof.

30. The method of Claim 29, in which the immunoselection technology is flow cytometry.

31. The method of Claim 28, in which the selective culture condition comprises plating the cells onto plastic, onto hyaluronans or onto plastic optionally coated with collagen IV, collagen III, laminin, hyaluronans, other matrix components from embryonic, fetal, neonatal tissues or combinations thereof.

32. The method of Claim 28 further comprising incubating the cells in serum-free medium comprising a basal medium with low calcium, no copper, and supplemented with insulin, transferrin/Fe, selenium, zinc, free fatty acids bound to serum albumin and, optionally, high density lipoprotein.

33. The method of Claim 32, in which the basal medium comprises RPMI 1640.

34. The method of Claim 32, in which the basal medium comprises less than 0.5 mM calcium.

35. The method of Claim 28 in which the cells are cultured for 7-21 days or longer.

36. The method of Claim 27 in which the biliary tree tissue comprises hilum, common hepatic duct, cystic duct, common duct, common hepato-pancreatic duct and gallbladder, or combinations thereof.

37. The method of Claim 27 in which the biliary tree tissue is derived from sites at which the biliary tree branches or contains high numbers of peribiliary glands.

38. A method of identifying and isolating a population of mammalian multipotent cells comprising mammalian multipotent stem/progenitor cells capable of differentiating into

multiple endodermal lineages, wherein the cells are obtained from biliary tree tissue of a mammal, the method comprising obtaining biliary tree tissue and then sequentially, in any order, or substantially simultaneously obtaining cells positive for:

- (i) at least one marker indicative of early liver cell lineage stages;
- (ii) at least one marker indicative of early pancreatic cell lineage stages;
- and at least one marker selected from one or more of those in categories (a)-(c):
- (a) at least one surface marker found on stem/progenitors;
- (b) at least one transcription factor indicative of endodermal stem/progenitors; and
- (c) weak to moderate expression of a pluripotency gene.

39. A method of identifying and isolating a population of mammalian multipotent cells enriched for the mammalian multipotent stem/progenitor cell according to Claim 1, comprising obtaining biliary tree tissue and then sequentially, in any order, or substantially simultaneously obtaining cells positive for:

- (i) at least one marker indicative of early liver cell lineage stages;
- (ii) at least one marker indicative of early pancreatic cell lineage stages;
- and at least one marker selected from one or more of those in categories (a)-(c):
- (a) at least one surface marker found on stem/progenitors;
- (b) at least one transcription factor indicative of endodermal stem/progenitors; and
- (c) weak to moderate expression of a pluripotency gene.

40. The method of Claim 38 or 39, in which the at least one marker indicative of early stage liver cell lineages is HNF6, HES1, CK19, albumin, or AFP.

41. The method of Claim 38 or 39, in which the at least one marker indicative of early stage pancreatic cell lineages is PDX1, PROX1, NGN3, or insulin.

42. The method of Claim 38 or 39, in which at least one surface marker found on stem/progenitor cells is CD133 (prominin), CD44H (hyaluronan receptor), N-CAM, CXCR4, or EpCAM.

43. The method of Claim 38 or 39, in which at least one transcription factor indicative of endodermal stem/progenitors is SOX 9, SOX17, or FOXA2.

44. The method of Claim 38 or 39, in which the pluripotency gene is SOX2, NANOG, KLF4, OCT4A or OCT4.

45. A method of propagating and/or expanding the mammalian multipotent stem/progenitor cell according to Claim 1, or a population comprising such cells or enriched



for such cells, comprising: culturing the cells on plastic or hyaluronans, or optionally on plastic coated with type III or IV collagen or hyaluronan or other matrix component derived from fetal, neonatal, or embryonic tissue and in a basal medium containing no copper, low calcium ( $<0.5$  mM), insulin, transferrin/Fe, a mixture of free fatty acids bound to serum albumin, and optionally, high density lipoprotein.

46. A method of propagating and/or expanding partner cells of the mammalian multipotent stem/progenitor cell according to Claim 1, comprising: culturing the cells on plastic or hyaluronans, or optionally on plastic coated with type III or IV collagen or hyaluronan or other matrix component derived from fetal, neonatal, or embryonic tissue and in a basal medium containing no copper, low calcium ( $<0.5$  mM), insulin, transferrin/Fe, a mixture of free fatty acids bound to serum albumin, and optionally, high density lipoprotein, wherein such partner cells comprise mesenchymal cells, angioblasts and stellate cells or precursors.

47. A method of lineage restricting mammalian multipotent stem/progenitor cells capable of differentiating into multiple endodermal lineages, and/or multipotent cell populations comprising or enriched for such mammalian multipotent stem/progenitor cells, to liver cells, the method comprising:

(a) obtaining a cell suspension comprising mammalian multipotent stem/progenitor cells capable of differentiating into multiple endodermal lineages, wherein the cells are obtained from biliary tree tissue of a mammal;

(b) embedding the cell suspension into a hydrogel comprising hyaluronan or hyaluronan combined with other matrix components; and

(c) culturing the cell suspension in basal medium supplemented with copper, calcium ( $\geq 0.5$  mM), insulin, transferrin/Fe, bFGF, hydrocortisone, glucagon, galactose, tri-iodothyroxine (T3), epidermal growth factor (EGF), hepatocyte growth factor (HGF), high density lipoprotein, and a mixture of free fatty acids bound to albumin, for a time sufficient to allow their differentiation into liver cells.

48. The method of Claim 47, in which the other matrix components comprise type IV collagen, laminin, or both.

49. The method of claim 47, in which the culturing is for 7-14 days.

50. A method of lineage restricting mammalian multipotent stem/progenitor cells capable of differentiating into multiple endodermal lineages, and/or multipotent cell

populations comprising or enriched for such mammalian multipotent stem/progenitor cells, to pancreas cells, the method comprising:

(a) obtaining a cell suspension comprising the mammalian multipotent stem/progenitor cells mammalian multipotent stem/progenitor cells capable of differentiating into multiple endodermal lineages, wherein the cells are obtained from biliary tree tissue of a mammal;

(b) embedding the cell suspension into a hydrogel comprising hyaluronans or hyaluronans combined with other matrix components; and

(c) culturing the cells in a basal medium supplemented with copper, calcium ( $\geq 0.5\text{mM}$ ), B27, ascorbic acid, insulin, transferrin/Fe, bFGF, cyclopamine, retinoic acid, exendin 4, high density lipoprotein, and a mixture of free fatty acids bound to albumin; and lacking hydrocortisone for a time sufficient to allow their differentiation into pancreatic cells.

51. The method of Claim 50, in which the other matrix components comprise type IV collagen, laminin, or both.

52. A method of lineage restricting mammalian multipotent stem/progenitor cells capable of differentiating into multiple endodermal lineages, and/or multipotent cell populations comprising or enriched for such mammalian multipotent stem/progenitor cells, to biliary tree cells, comprising:

(a) obtaining a cell suspension comprising the mammalian multipotent stem/progenitor cells mammalian multipotent stem/progenitor cells capable of differentiating into multiple endodermal lineages, wherein the cells are obtained from biliary tree tissue of a mammal;

(b) embedding the cell suspension into a hydrogel comprising hyaluronans or hyaluronans in combination with other matrix components; and

(c) culturing the cells in a basal medium supplemented with copper, calcium ( $\geq 0.5\text{mM}$ ), insulin, transferrin/Fe, hydrocortisone, bFGF, vascular endothelial cell growth factor (VEGF), hepatocyte growth factor (HGF), high density lipoprotein, and a mixture of free fatty acids bound to albumin, for a time sufficient for their differentiation into cholangiocytes.

53. The method of Claim 52, in which biliary tree cells comprise cholangiocytes.

54. The method of Claim 52, in which the other matrix components comprises type I collagen.

55. A method of differentiating cells *in vivo*, comprising transplanting the mammalian multipotent stem/progenitor cells of Claim 1, or populations comprising such cells or enriched for such cells, *in vivo* as cell suspensions or as implants or grafts, with or without prior lineage restriction under appropriate culture conditions, into the liver where they differentiate to liver tissue.

56. A method of differentiating cells *in vivo*, comprising transplanting the mammalian multipotent stem/progenitor cells of Claim 1, or populations comprising such cells or enriched for such cells, *in vivo* as cell suspensions or as implants or grafts, with or without prior lineage restriction under appropriate culture conditions, into the bile duct where they differentiate into biliary tree tissue.

57. A method of differentiating cells *in vivo*, comprising transplanting the mammalian multipotent stem/progenitor cells of Claim 1, populations comprising such cells or enriched for such cells, *in vivo* as cell suspensions or as implants or grafts, with or without prior lineage restriction under appropriate culture conditions into the pancreas, under the kidney capsule or into the epididymal fat pads, where they differentiate into functional pancreatic tissue.

1/26




FIG. 1

2/26




FIG. 2

EXTRAHEPATIC BILIARY TREE (N=5)	GALLBLADDER	CYSTIC DUCT	HEPATIC HILUM (COMMON HEPATIC DUCT)	BILE DUCT	HEPATO-PANCREATIC AMPULLA
SURFACE OCCUPIED BY PBGS (%)	/	3.22 ± 0.87 (0.39)	3.68 ± 0.79 (0.35)	1.29 ± 0.37 (0.16)*	7.47 ± 2.20 (0.98)*
AVERAGE NUMBER OF PBGS/ FIELD (20x)	/	8.15 ± 2.03 (0.91)	10.25 ± 2.27 (1.01)	4.37 ± 1.15 (0.51)*	27.83 ± 3.16 (1.41)*
AVERAGE CIRCUMFERENCE OF PBGS (µm)	/	115.07 ± 9.11 (4.07)	106.44 ± 19.79 (8.85)	101.01 ± 10.44 (4.67)	130.95 ± 14.22 (6.36)*

FIG. 3a




FIG. 3b

4/26




FIG. 4

5/26




FIG. 5b




FIG. 5a



6/26




FIG. 6

7/26





FIG. 7

8/26




FIG. 8

9/26




FIG. 9

10/26




FIG. 10b




FIG. 10d




FIG. 10a




FIG. 10c

11/26




FIG. 11a




FIG. 11b



12/26




FIG. 11d



FIG. 11c




FIG. 11e

13/26




FIG. 12



14/26




FIG. 13




FIG. 13a




FIG. 13b




FIG. 13c




FIG. 13d




FIG. 13e




FIG. 14

16/26




FIG. 15

17/26




FIG. 16

18/26




FIG. 17a




FIG. 17b

CONTROL CONDITION	SCORING: SEMI-QUANTITATIVE ESTIMATE OF CHOLANGIOCYTES OR HEPATOCYTES	
	SR+/CFTR+ CELLS	ALB+ /CK18+ CELLS
STEM CELL CONTROLS	$0.2 \pm 0.4$	0
HDM CONTROLS	$3 \pm 0.7^*$	$2.2 \pm 0.8^*$

FIG. 17c



19/26




FIG. 18a




FIG. 18b




FIG. 18c




FIG. 18d




FIG. 18e

ISLET-LIKE STRUCTURES (c-pep+)	
STEM CELL CONTROLS	$1 \pm 0.7$
HDM-P CONTROLS	$3.8 \pm 1.3^*$

FIG. 18f




FIG. 18g




FIG. 18h

20/26






FIG. 19

21/26




FIG. 20a




FIG. 20b



FIG. 20c




FIG. 20d




FIG. 20e




FIG. 20f




FIG. 20g




FIG. 20h



22/26




FIG. 20i




FIG. 21b




FIG. 21d




FIG. 21a



FIG. 21c

24/26




FIG. 22

25/26





FIG. 23

26/26




FIG. 24




FIG. 25

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 10/54450

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(8) - C12N 5/071 (2011.01)

USPC - 435/370

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC(8): C12N 5/071 (2011.01)

USPC: 435/370

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

USPC: 435/375, 435/377, 435/325

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

PubWEST (PGPB,USPT,USOC,EPAB,JPAB); Google Scholar

Search terms used: biliary (tree OR tract) peribiliary stem cell (liver OR hepat\$) bile duct multipotent endoderm\$ (express\$ OR marker) (HNF6 OR HES1 OR CK19 OR albumin OR AFP) (POXI OR PROXI OR NGN3 OR insulin) pancrea\$

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2009/0191159 A1 (SAKURADA et al.) 30 July 2009 (30.07.2009), entire document, especially: para [0003], [0087], [0089], [0090], [0252], [0254], [0288]	1-26
Y	US 2007/0099297 A1 (REID et al.) 3 May 2007 (03.05.2007), entire document, especially: para [0002], [0012], [0023]-[0025], [0030], [0059], [0067], [0089]	1-26
Y	US 2009/0092586 A1 (VERFAILLIE et al.) 9 April 2009 (09.04.2009), Abstract; para [0006], [0013]-[0021], [0063]	10-16, 18-24
Y	US 2003/0229045 A1 (HARRIS) 11 December 2003 (11.12.2003), para [0005]	20
Y	US 2007/0036765 A1 (CIVIN et al.) 15 February 2007 (15.02.2007), para [0246]	21
Y	GOLDING et al., Reactive Biliary Epithelium: The Product of a Pluripotent Stem Cell Compartment?, Human Pathology. September 1996, Vol. 27, No. 9, pp. 872-884, pg. 874, col. 1, para 2; pg. 878, col. 2, para 4	8, 9, 24
Y	ALISON et al., Pluripotent liver stem cells: facultative stem cells located in the biliary tree. Cell Prolif., July 1996, Vol 29, No 7, pp 373-402, abstract.	1

☐ Further documents are listed in the continuation of Box C.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

14 February 2011 (14.02.2011)

Date of mailing of the international search report

28 FEB 2011

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner for Patents  
P.O. Box 1450, Alexandria, Virginia 22313-1450

Facsimile No. 571-273-3201

Authorized officer:

Lee W. Young

PCT Helpdesk: 571-272-4300  
PCT OSP: 571-272-7774

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 10/54450

## Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Group I: Claims 1-26, drawn to compositions comprising mammalian multipotent stem/progenitor cells capable of differentiating into multiple endodermal lineages.

Group II: Claims 27-44, drawn to methods of obtaining, identifying, or isolating mammalian multipotent stem/progenitor cells capable of differentiating into multiple endodermal lineages.

Group III: Claims 45-54, drawn to methods of propagating, expanding, or lineage restricting a mammalian multipotent stem/progenitor cell capable of differentiating into multiple endodermal lineages.

Group IV: Claims 55-57, drawn to methods of differentiating cells in vivo.

---please see extra sheet---

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-26

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

Continuation of:

Box No. III Observations where unity of invention is lacking

The inventions listed as Groups I-IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical features shared by the inventions listed as Groups I-IV are mammalian multipotent stem/progenitor cells capable of differentiating into multiple endodermal lineages, wherein the cells are obtained from biliary tree tissue of a mammal. This shared technical feature does not provide a contribution over the prior art, as evidenced by the article entitled "Pluripotential liver stem cells: facultative stem cells located in the biliary tree" by Alison et al. (Cell Prolif., July 1996, Vol 29, No 7, pp 373-402; hereinafter 'Alison'). Alison discloses pluripotent stem cells obtained from the biliary tree of the liver that are capable of proliferating and differentiating into hepatocytes and other cell types (abstract). As one of ordinary skill in the art would know, pluripotent stem cells are defined as cells that have the potential to differentiate into any fetal or adult cell type, which includes but is not limited to cells of multiple endodermal lineages. In the absence of a contribution over the prior art, the shared technical feature is not a shared special technical feature. Without a shared special technical feature, the inventions lack unity with one another.

Furthermore, the special technical feature of Group II are the method steps of obtaining cells that are positive for specific markers. This special technical feature is not shared by the inventions listed as Groups I, III, and IV. The special technical feature of Group III are the method steps of culturing cells on a specific substrate and in a basal medium. This special technical feature is not shared by the inventions listed as Groups I, II, and IV. The special technical feature of Group IV are the method steps of transplanting cells and allowing the cells to differentiate in vivo. This special technical feature is not shared by the inventions listed as Groups I, II, and III. Accordingly, the inventions listed as Groups I-IV do not share a special technical feature. In the absence of a shared special technical feature, the inventions lack unity with one another.